Sweet Ping Ng1, Houda Bahig2, Amit Jethanandani3, Courtney Pollard3, Joel Berends3, Erich M Sturgis4, Faye M Johnson5, Baher Elgohari3, Hesham Elhalawani3, David I Rosenthal3, Heath D Skinner6, G Brandon Gunn3, Jack Phan3, Steven J Frank3, Abdallah S R Mohamed3, Clifton D Fuller3, Adam S Garden7. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. Electronic address: sweet.ng@petermac.org. 2. Department of Radiation Oncology, Centre Hospitalier de l'Universite de Montreal, Canada. 3. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. 4. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA. 5. Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. 6. Department of Radiation Oncology, UPMC Hillman Cancer Centers, Pittsburgh, USA. 7. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: agarden@mdanderson.org.
Abstract
PURPOSE/ OBJECTIVE: Radiation-induced lymphopenia has been associated with poor survival outcomes in certain solid tumors such as esophageal, lung, cervical and pancreatic cancers. We aim to determine the effect of treatment-related lymphopenia during radiotherapy on outcomes of patients with oropharyngeal cancer. MATERIALS/ METHODS: A retrospective analysis of all patients who completed definitive radiotherapy for oropharyngeal cancer at The University of Texas MD Anderson Cancer Center and had blood counts taken during radiotherapy from 2002 to 2013 were included. Patient, tumor and treatment characteristics, clinical outcomes and lymphocyte counts during radiotherapy were recorded. Lymphopenia was graded according to the CTCAE v4.0. Survival rates were estimated using the Kaplan-Meier method and compared with log-rank tests. RESULTS: 850 patients were evaluated. The median age was 57 years. The majority of the cohort had p16/HPV-positive disease (71%), 8% had HPV-negative disease and 21% were unknown. The median radiation total dose was 70 Gy. 45% of patients had induction chemotherapy, and 87% had concurrent chemotherapy. 703 (83%) patients developed ≥grade 3 (G3) lymphopenia and 209 (25%) had grade 4 (G4) lymphopenia during radiotherapy. The median follow-up was 59 months; the 5-year overall survival rate was 81%. There were no significant differences in overall survival rates nor in disease control rates, in those who developed G3/G4 lymphopenia compared with those who did not. No significant effect of lymphopenia on survival was observed when analyzed according to p16/HPV status. CONCLUSION: In this large cohort of patients with oropharyngeal cancer, the development of lymphopenia during radiotherapy did not impact outcomes.
PURPOSE/ OBJECTIVE: Radiation-induced lymphopenia has been associated with poor survival outcomes in certain solid tumors such as esophageal, lung, cervical and pancreatic cancers. We aim to determine the effect of treatment-related lymphopenia during radiotherapy on outcomes of patients with oropharyngeal cancer. MATERIALS/ METHODS: A retrospective analysis of all patients who completed definitive radiotherapy for oropharyngeal cancer at The University of Texas MD Anderson Cancer Center and had blood counts taken during radiotherapy from 2002 to 2013 were included. Patient, tumor and treatment characteristics, clinical outcomes and lymphocyte counts during radiotherapy were recorded. Lymphopenia was graded according to the CTCAE v4.0. Survival rates were estimated using the Kaplan-Meier method and compared with log-rank tests. RESULTS: 850 patients were evaluated. The median age was 57 years. The majority of the cohort had p16/HPV-positive disease (71%), 8% had HPV-negative disease and 21% were unknown. The median radiation total dose was 70 Gy. 45% of patients had induction chemotherapy, and 87% had concurrent chemotherapy. 703 (83%) patients developed ≥grade 3 (G3) lymphopenia and 209 (25%) had grade 4 (G4) lymphopenia during radiotherapy. The median follow-up was 59 months; the 5-year overall survival rate was 81%. There were no significant differences in overall survival rates nor in disease control rates, in those who developed G3/G4 lymphopenia compared with those who did not. No significant effect of lymphopenia on survival was observed when analyzed according to p16/HPV status. CONCLUSION: In this large cohort of patients with oropharyngeal cancer, the development of lymphopenia during radiotherapy did not impact outcomes.
Authors: Lester J Peters; Brian O'Sullivan; Jordi Giralt; Thomas J Fitzgerald; Andy Trotti; Jacques Bernier; Jean Bourhis; Kally Yuen; Richard Fisher; Danny Rischin Journal: J Clin Oncol Date: 2010-05-17 Impact factor: 44.544
Authors: Derrick Wansom; Emily Light; Dafydd Thomas; Francis Worden; Mark Prince; Susan Urba; Douglas Chepeha; Bhavna Kumar; Kitrina Cordell; Avraham Eisbruch; Jeremy Taylor; Jeffrey Moyer; Carol Bradford; Nisha D'Silva; Thomas Carey; Jonathan McHugh; Gregory Wolf Journal: Laryngoscope Date: 2012-01 Impact factor: 3.325
Authors: Amy Anne D Lassig; Anne M Joseph; Bruce R Lindgren; Patricia Fernandes; Sarah Cooper; Chelsea Schotzko; Samir Khariwala; Margaret Reynolds; Bevan Yueh Journal: Otolaryngol Head Neck Surg Date: 2012-08-08 Impact factor: 3.497
Authors: Jiayi Huang; Todd A DeWees; Shahed N Badiyan; Christina K Speirs; Daniel F Mullen; Sandra Fergus; David D Tran; Gerry Linette; Jian L Campian; Michael R Chicoine; Albert H Kim; Gavin Dunn; Joseph R Simpson; Clifford G Robinson Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-08 Impact factor: 7.038
Authors: Chad Tang; Zhongxing Liao; Daniel Gomez; Lawrence Levy; Yan Zhuang; Rediet A Gebremichael; David S Hong; Ritsuko Komaki; James W Welsh Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-08 Impact factor: 7.038
Authors: Yutaka Shiraishi; Penny Fang; Cai Xu; Juhee Song; Sunil Krishnan; Eugene J Koay; Reza J Mehran; Wayne L Hofstetter; Mariela Blum-Murphy; Jaffer A Ajani; Ritsuko Komaki; Bruce Minsky; Radhe Mohan; Charles C Hsu; Brian P Hobbs; Steven H Lin Journal: Radiother Oncol Date: 2017-12-14 Impact factor: 6.280
Authors: Brian De; Ethan B Ludmir; Craig A Messick; Matthew C Cagley; Van K Morris; Prajnan Das; Bruce D Minsky; Cullen M Taniguchi; Grace L Smith; Eugene J Koay; Albert C Koong; Radhe Mohan; Emma B Holliday Journal: J Gastrointest Oncol Date: 2021-10
Authors: Gyu Sang Yoo; Jeong Il Yu; Sungkoo Cho; Youngyih Han; Yoonjin Oh; Do Hoon Lim; Hee Rim Nam; Ji-Won Lee; Ki-Woong Sung; Hyung Jin Shin Journal: Cancer Res Treat Date: 2021-10-15 Impact factor: 5.036